|
Sign In to gain access to subscriptions and/or personal tools.
|
Pharmacokinetic Considerations for Selection of HAART in Treatment-Naive HIV-Infected Individuals, 2008: More Than It Seems?
Andrew D. Luber*
Garden State Infectious Diseases
* To whom correspondence should be addressed. E-mail: a.luber{at}earthlink.net.
 |
Abstract |
|---|
The selection of highly active antiretroviral therapy for treatment-naive HIV-infected individuals is complex. In addition to patient adherence, exposures of antiretroviral agents (ARVs) can be influenced by patient population, gender, drug–drug and drug–food interactions, and comorbid medical conditions. In contrast to pharmacokinetic sampling performed under controlled conditions, ARV exposures in "real-world" clinical practice display substantial interpatient variability. The interactions between ARVs and other medications commonly used by HIV-infected patients could significantly impact ARV exposures and need to be considered when selecting therapies. Pharmacogenomic differences have been identified for a number of ARVs, resulting in increased plasma exposures (efavirenz, nelfinavir) or increased risk for adverse drug events (atazanavir, abacavir, indinavir). Despite increasing populations of HIV-infected females and people 50 years or older, the pharmacokinetics of many ARVs has not been adequately studied in these patient populations. The clinical significance of many of these pharmacokinetic differences is unknown.
First published on March 4, 2008, doi:10.1177/1545109708315364
Journal of the International Association of Physicians in AIDS Care (JIAPAC) 2008;7:10.
A more recent version of this article appeared on March 1, 2008
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
|
|
